Indonesia vs Northern Africa and Western Asia: Percentage of bloodstream infection due to Escherichia coli resistant
Indonesia
69.7%
in 2022
Northern Africa and Western Asia
52.4%
in 2022
Indonesia rank
8th
Northern Africa and Western Asia rank
7th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Indonesia
- Northern Africa and Western Asia
How they compare
Indonesia currently reports 69.7% against 52.4% in Northern Africa and Western Asia, a difference of 17.3%.
That makes Indonesia's figure about 1.3 times Northern Africa and Western Asia's.
Across all 5 years both countries report, Indonesia has been ahead every year.
Indonesia ranks 8th and Northern Africa and Western Asia ranks 7th of 50 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Northern Africa and Western Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71.0% | 54.7% | 16.3% | Indonesia |
| 2020s | 72.2% | 53.7% | 18.5% | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Indonesia or Northern Africa and Western Asia?
- Indonesia, at 69.7% against 52.4% in Northern Africa and Western Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Indonesia and Northern Africa and Western Asia?
- 17.3%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Northern Africa and Western Asia?
- 5 years are reported by both, from 2018 to 2022.
- How do Indonesia and Northern Africa and Western Asia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Indonesia ranks 8th and Northern Africa and Western Asia ranks 7th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.